August 18-20, 2020
Applied BioMath Presence
Title and Abstract: Assessing the Current Status of Cell Engagers
Following the first approval of blinatumomab in 2014, therapeutics designed to utilize immune cell engagement have continued to gather favor with the pharmaceutical industry. As our understanding of immune cell biology and immunotherapy has expanded, so to have the potential to improve therapeutic options.
This workshop will review of the core mechanisms of cell engagement (T cell Engagers, NK cell engagers, CAR-T cells, etc.) as well as address some of the common challenges associated with these approaches e.g. on-target offtumor toxicity and Cytokine Release Syndrome (CRS).
Attend this session and learn more about how to maximize the therapeutic index of cell engagers:
- What does the target landscape show are the “lowest hanging fruit” – liquid or solid tumors?
- Current strategies for selection of lead candidates
- Review preclinical assays used to evaluate cell engagers in vitro and in vivo
- Lessons learned from early generation T cell engagers in reduction of CRS and other tox issues
- Emerging technologies to maximize efficacy
Workshop Leader: Joshua Apgar, CSO & Co-founder, Applied BioMath
Conference Day Two Presentation
Title and Abstract: Use of Quantitative Systems Pharmacology (QSP) modeling to drive decision making of T cell engager mAbs from target identification to Phase 1
- Target feasibility and selection
- Optimising drug format and Kds - impact on therapeutic window between low and high expressing cells
- Translation from in vitro to in vivo data to the clinic
- Predicting clinical starting and efficacious doses
Presenter: Alison Betts, Senior Director of Scientific Collaborations and Fellow of Modeling & Simulation, Applied BioMath